NASDAQ:NK NantKwest (NK) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.33▼$5.7250-Day Range$16.09▼$38.7052-Week Range$2.52▼$45.42Volume2.50 million shsAverage Volume1.57 million shsMarket Capitalization$600.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get NantKwest alerts: Email Address Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About NantKwest Stock (NASDAQ:NK)NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Read More Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. NK Stock News HeadlinesFebruary 4, 2024 | time.comSpace Nk Promo CodesAugust 13, 2023 | mirror.co.ukFrankie Bridge shares her new Space NK beauty buys including concealer people 'love'July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 13, 2023 | msn.comPiper Sandler Downgrades ImmunityBio (IBRX)May 12, 2023 | investing.comNantKwest Inc (IBRX) Earnings Dates & ReportsMay 10, 2023 | marketwatch.comNK Cells Market Report | Research Across The World 2031March 9, 2023 | marketwatch.comNatural Killer Cell Therapy Market Size, Growth | Soaring Demand | 2023 - 2029January 12, 2023 | marketwatch.comNatural Killer Cell Therapy Market 2023 Statistics, Share Price, Growth Prospects, Industry Trends till 2028July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.November 26, 2022 | marketwatch.comNK Cell Therapy Market Insights: Industry changing aspects, New Technologies and Forecast to 2025 | Market Growth ReportsSeptember 29, 2022 | marketwatch.comNatural Killer Cells Therapeutics Market 2022 : Top Manufacturers, Key Trends, Progression Status and Business Trends to 2027August 22, 2022 | marketwatch.comNatural Killer Cell Therapy Market 2022 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2026August 12, 2022 | finance.yahoo.comGlobal Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities - Yahoo FinanceAugust 11, 2022 | benzinga.comGlobal Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical The - BenzingaJuly 6, 2022 | finance.yahoo.comHarpoon Therapeutics Expands Leadership Team - Yahoo FinanceJune 18, 2022 | streetinsider.comCelldex (CLDX) Appoints Cheryl L. Cohen and Dr. Garry Neil to its Board - StreetInsider.comJune 16, 2022 | finance.yahoo.comCelldex Announces Two New Appointments to its Board of Directors - Yahoo FinanceMay 13, 2022 | prnewswire.comImmPACT Bio Names Sylvain Roy as Chief Technology Officer - PR NewswireSee More Headlines Receive NK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NK CUSIPN/A CIK1326110 Webwww.nantkwest.com Phone858-633-0300FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,790,000.00 Net Margins-76,658.58% Pretax MarginN/A Return on Equity-56.06% Return on Assets-46.93% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual Sales$40,000.00 Price / Sales15,007.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book4.46Miscellaneous Outstanding Shares109,345,000Free FloatN/AMarket Cap$600.30 million OptionableNot Optionable Beta2.61 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Barry J. Simon (Age 56)Pres, Chief Admin. Officer & Exec. Director Comp: $454.44kMs. Sonja Nelson (Age 48)Chief Financial Officer Comp: $442.69kMr. Richard Gerald Adcock (Age 52)Chief Exec. Officer Mr. Steven Yang J.D.VP, Gen. Counsel & Corp. Sec.Dr. Jerel A. Banks Ph.D. (Age 46)M.D., Sr. VP Mergers and Acquisitions Mr. Leonard S. SenderSr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult OncologyDr. Hans Georg Klingemann (Age 71)VP of R&D More ExecutivesKey CompetitorsPrecigenNASDAQ:PGENZIOPHARM OncologyNASDAQ:ZIOPbluebird bioNASDAQ:BLUECellectisNASDAQ:CLLSIovance BiotherapeuticsNASDAQ:IOVAView All Competitors NK Stock Analysis - Frequently Asked Questions How were NantKwest's earnings last quarter? NantKwest, Inc. (NASDAQ:NK) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%. What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO? 14 employees have rated NantKwest Chief Executive Officer Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among the company's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. When did NantKwest IPO? NantKwest (NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager. What other stocks do shareholders of NantKwest own? Based on aggregate information from My MarketBeat watchlists, some other companies that NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Dynavax Technologies (DVAX). This page (NASDAQ:NK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.